Medication Shortage Affects Cancer Treatment in Marrakech
Residents of Marrakech are expressing their deep concerns over the prolonged shortage of the medication known as Zometa (Zoledronic Acid) at Ibn Tofail Hospital. This critical drug, integral to the treatment regimen for cancer patients, has been unavailable for several months, leaving many patients in dire situations without essential care. According to reports received by the online publication Hespress, the continuous unavailability of this medication for the past six months has led to significant distress among cancer patients who rely on it as part of their therapeutic journey. Families find themselves not only grappling with the emotional toll of cancer but also facing financial hardships, as they may not be able to afford purchasing the medication from outside the hospital.
Despite the extensive duration of the shortage, patients remain hopeful for the return of the medication, although there is no clear indication of when it might be available again. Zometa is a supportive cancer treatment that helps prevent complications in adults with advanced cancer affecting the bones. It is known to reduce the risk of fractures, spinal compression, and the need for radiation therapy or surgery on the bones, as reported by the specialized news platform “everyone.” In Marrakech, this medication is primarily provided through a department under the Oncology and Hematology Hospital affiliated with the Mohammed VI University Hospital Center, although its operations are based at Ibn Tofail Hospital.
Procurement Challenges and Supply Issues
An insider from the Oncology and Hematology Hospital confirmed the reported shortage, clarifying that the issue does not stem from their management. They indicated that the Ministry of Health and Social Protection is actively issuing tenders for the procurement of the medication, yet no companies have submitted bids. The source stated, “The tenders are being issued, but no one is coming forward to submit their proposals.” Furthermore, it remains unclear how long the medication has actually been in short supply, as the report claims a six-month period.
A union representative also confirmed that there is a high demand for Zometa, yet no companies are participating in the tenders. They noted that distribution companies are reluctant to engage with public sector tender requests. Additionally, the representative highlighted a worrying trend where several pharmaceutical laboratories have reduced their production post-COVID-19, and the decrease in medication prices has led some companies to perceive profit margins as inadequate.
As reported by hespress.com.
